• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Butterfly Network Inc.

    7/17/26 4:20:19 PM ET
    $BFLY
    Medical Electronics
    Health Care
    Get the next $BFLY alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 10)


    Butterfly Network, Inc.

    (Name of Issuer)


    Class A common stock, par value $0.0001 per share, Class B common stock, par value $0.0001 per share

    (Title of Class of Securities)




    124155102

    (CUSIP Number)
    Jonathan M. Rothberg, Ph.D.
    c/o Butterfly Network, Inc., 1600 District Avenue
    Burlington, MA, 01803
    (781) 557-4800

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    07/15/2026

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    schemaVersion:


    SCHEDULE 13D

    CUSIP Number(s):
    124155102


    1 Name of reporting person

    Rothberg Jonathan M.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    102,079.00
    8Shared Voting Power

    726,696.00
    9Sole Dispositive Power

    102,079.00
    10Shared Dispositive Power

    726,696.00
    11Aggregate amount beneficially owned by each reporting person

    828,775.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.4 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    This Reporting Person's table is for Class A common stock. Rows 7, 9 and 11 consists of (i) 80,434 shares of Class A common stock of Butterfly Network, Inc. (f/k/a Longview Acquisition Corp.) (the "Issuer") held by Jonathan M. Rothberg, Ph.D. and (ii) stock options to purchase 21,645 shares of Class A common stock of the Issuer which are exercisable within 60 days of July 17, 2026, held by Dr. Jonathan M. Rothberg. Rows 8, 10 and 11 consists of 726,696 shares of Class A common stock of the Issuer held by Dr. Rothberg's spouse. Row 13 is calculated based on 234,842,768 shares of Class A common stock of the Issuer outstanding as of April 20, 2026.


    SCHEDULE 13D

    CUSIP Number(s):
    124155102


    1 Name of reporting person

    Rothberg Jonathan M.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    25,213,303.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    25,213,303.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    25,213,303.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    100 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    This Reporting Person's table is for Class B common stock. Rows 7, 9 and 11 consists of 25,213,303 shares of Class B common stock of the Issuer held by 4C Holdings I, LLC, 4C Holdings II, LLC, 4C Holdings III, LLC, 4C Holdings IV, LLC and 4C Holdings V, LLC and shares distributed from 4C Holdings I, LLC and held by entities owned by trusts created for the benefit of Dr. Jonathan Rothberg's children. Row 13 is calculated based on 25,213,303 shares of Class B common stock of the Issuer outstanding as of July 17, 2026.


    SCHEDULE 13D

    CUSIP Number(s):
    124155102


    1 Name of reporting person

    4C Holdings I, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    4,716,596.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    4,716,596.00
    11Aggregate amount beneficially owned by each reporting person

    4,716,596.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    18.7 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    This Reporting Person's table is for Class B common stock. Row 13 is calculated based on 25,213,303 shares of Class B common stock of the Issuer outstanding as of July 17, 2026.


    SCHEDULE 13D

    CUSIP Number(s):
    124155102


    1 Name of reporting person

    4C Holdings II, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    2,621,701.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    2,621,701.00
    11Aggregate amount beneficially owned by each reporting person

    2,621,701.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    10.4 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    This Reporting Person's table is for Class B common stock. Row 13 is calculated based on 25,213,303 shares of Class B common stock of the Issuer outstanding as of July 17, 2026.


    SCHEDULE 13D

    CUSIP Number(s):
    124155102


    1 Name of reporting person

    4C Holdings III, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    2,621,701.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    2,621,701.00
    11Aggregate amount beneficially owned by each reporting person

    2,621,701.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    10.4 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    This Reporting Person's table is for Class B common stock. Row 13 is calculated based on 25,213,303 shares of Class B common stock of the Issuer outstanding as of July 17, 2026.


    SCHEDULE 13D

    CUSIP Number(s):
    124155102


    1 Name of reporting person

    4C Holdings IV, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    2,621,701.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    2,621,701.00
    11Aggregate amount beneficially owned by each reporting person

    2,621,701.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    10.4 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    This Reporting Person's table is for Class B common stock. Row 13 is calculated based on 25,213,303 shares of Class B common stock of the Issuer outstanding as of July 17, 2026.


    SCHEDULE 13D

    CUSIP Number(s):
    124155102


    1 Name of reporting person

    4C Holdings V, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    8,845,238.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    8,845,238.00
    11Aggregate amount beneficially owned by each reporting person

    8,845,238.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    35.1 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    This Reporting Person's table is for Class B common stock. Row 13 is calculated based on 25,213,303 shares of Class B common stock of the Issuer outstanding as of July 17, 2026.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Class A common stock, par value $0.0001 per share, Class B common stock, par value $0.0001 per share
    (b)Name of Issuer:

    Butterfly Network, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    1600 District Avenue, Burlington, MASSACHUSETTS , 01803.
    Item 1 Comment:
    Explanatory Note This Amendment No. 10 to Schedule 13D ("Amendment No. 10") amends and supplements the Schedule 13D filed on February 22, 2021, as amended by Amendment No. 1 filed on March 26, 2021, Amendment No. 2 filed on March 28, 2022, Amendment No. 3 filed on September 16, 2022, Amendment No. 4 filed on September 13, 2023, Amendment No. 5 filed on August 30, 2024, Amendment No. 6 filed on March 7, 2025, Amendment No. 7 filed on December 1, 2025, Amendment No. 8 filed on December 17, 2025 and Amendment No. 9 filed on March 17, 2026 (as amended, the "Schedule 13D") relating to the Class A common stock, par value $0.0001 per share, and Class B common stock, par value $0.0001 per share, of Butterfly Network, Inc. (f/k/a Longview Acquisition Corp.), a Delaware corporation (the "Issuer"). Information reported in the Schedule 13D remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment No. 10. Capitalized terms used but not defined herein have the meanings ascribed to them in the Schedule 13D.
    Item 4.Purpose of Transaction
     
    Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following:
    Item 5.Interest in Securities of the Issuer
    (c)
    Item 5 of the Schedule 13D is hereby amended and supplemented by adding the following: The following transactions were effected by the Reporting Persons since the most recent filing of the Reporting Persons on Schedule 13D. All transactions below were effected by the Reporting Persons in connection with estate planning and pursuant to a Rule 10b5-1 trading plan entered into on March 13, 2026. On July 14, 2026, 815,632 shares of Class A common stock were sold at a weighted average price per share of $7.7178. On July 15, 2026, 1,730,319 shares of Class A common stock were sold at a weighted average price per share of $7.3228. On July 16, 2026, 253,867 shares of Class A common stock were sold at a weighted average price per share of $7.0889. On July 16, 2026, 1,213,634 shares of Class B common stock were sold at a weighted average price per share of $7.0889. In accordance with its terms, the Class B common stock automatically converted into Class A common stock, on a one-to-one basis, upon sale.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Rothberg Jonathan M.
     
    Signature:/s/ Jonathan M. Rothberg
    Name/Title:Jonathan M. Rothberg, Ph.D.
    Date:07/17/2026
     
    Rothberg Jonathan M.
     
    Signature:/s/ Jonathan M. Rothberg
    Name/Title:Jonathan M. Rothberg, Ph.D.
    Date:07/17/2026
     
    4C Holdings I, LLC
     
    Signature:/s/ Jonathan M. Rothberg
    Name/Title:Jonathan M. Rothberg, Ph.D., Manager
    Date:07/17/2026
     
    4C Holdings II, LLC
     
    Signature:/s/ Jonathan M. Rothberg
    Name/Title:Jonathan M. Rothberg, Ph.D., Manager
    Date:07/17/2026
     
    4C Holdings III, LLC
     
    Signature:/s/ Jonathan M. Rothberg
    Name/Title:Jonathan M. Rothberg, Ph.D., Manager
    Date:07/17/2026
     
    4C Holdings IV, LLC
     
    Signature:/s/ Jonathan M. Rothberg
    Name/Title:Jonathan M. Rothberg, Ph.D., Manager
    Date:07/17/2026
     
    4C Holdings V, LLC
     
    Signature:/s/ Jonathan M. Rothberg
    Name/Title:Jonathan M. Rothberg, Ph.D., Manager
    Date:07/17/2026
    Get the next $BFLY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFLY

    DatePrice TargetRatingAnalyst
    8/1/2025Outperform → Perform
    Oppenheimer
    7/1/2025$3.00Buy
    Craig Hallum
    3/17/2025Outperform
    William Blair
    9/10/2024$3.00Buy
    Lake Street
    3/29/2023$2.25Neutral
    UBS
    11/29/2022$4.50Outperform
    Oppenheimer
    10/4/2022$9.50Buy
    B. Riley Securities
    12/17/2021$7.00Neutral
    UBS
    More analyst ratings

    $BFLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Butterfly Network downgraded by Oppenheimer

    Oppenheimer downgraded Butterfly Network from Outperform to Perform

    8/1/25 12:44:19 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Craig Hallum initiated coverage on Butterfly Network with a new price target

    Craig Hallum initiated coverage of Butterfly Network with a rating of Buy and set a new price target of $3.00

    7/1/25 8:24:04 AM ET
    $BFLY
    Medical Electronics
    Health Care

    William Blair initiated coverage on Butterfly Network

    William Blair initiated coverage of Butterfly Network with a rating of Outperform

    3/17/25 7:23:53 AM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Butterfly Network to Report Second Quarter 2026 Financial Results on July 30, 2026

    Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, announced that it will report second quarter 2026 financial results on Thursday, July 30, 2026, at 8:00 am ET. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and John Doherty, Executive Vice President and Chief Financial Officer, will host a conference call and webcast before the market opens on July 30 to discuss the financial performance and operational progress. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly’s Investor Relations website at Events & Presentations.

    7/16/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Butterfly Network Expands its Handheld Ultrasound Availability into Brazil

    Expansion into one of Latin America's largest healthcare markets advances Butterfly's international growth strategy and mission to democratize medical imaging Butterfly Network, Inc. ("Butterfly") (NYSE:BFLY), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the commercial availability of its Butterfly iQ+ and iQ3 handheld ultrasound devices and mobile application in Brazil through a network of authorized distribution partners. Brazil is the largest medical device market in Latin America and one of the fastest-growing ultrasound markets globally,1,2 representing a significant opportunity to expand access to medical imagi

    7/2/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Butterfly Network’s Embedded™ Partner Aleph Neuro Unveils Stunning Brain Images

    Brain-computer interface research lab building on Butterfly's Ultrasound-on-Chip™ platform achieves what it deems a breakthrough in non-invasive neuroimaging, with implications for how humans may one day communicate and connect. Butterfly Network, Inc. ("Butterfly") (NYSE:BFLY), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today responded to Aleph Neuro (Aleph)'s public launch and announcement of what it describes as a breakthrough in non-invasive brain imaging using ultrasound. Aleph is a participant in the Butterfly Embedded™ licensing and co-development program powering a new wave of ultrasound-enabled technologies. This press rel

    6/25/26 5:02:00 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    SEC Filings

    View All

    SEC Form 144 filed by Butterfly Network Inc.

    144 - Butterfly Network, Inc. (0001804176) (Subject)

    7/20/26 5:09:42 PM ET
    $BFLY
    Medical Electronics
    Health Care

    SEC Form 144 filed by Butterfly Network Inc.

    144 - Butterfly Network, Inc. (0001804176) (Subject)

    7/20/26 4:20:33 PM ET
    $BFLY
    Medical Electronics
    Health Care

    SEC Form 144 filed by Butterfly Network Inc.

    144 - Butterfly Network, Inc. (0001804176) (Subject)

    7/20/26 3:12:02 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rothberg Jonathan M sold $20,765,302 worth of shares (2,799,818 units at $7.42) as part of a pre-agreed trading plan and sold $8,603,330 worth of Class B Common Stock (1,213,634 units at $7.09) as part of a pre-agreed trading plan, decreasing direct ownership by 96% to 105,881 units (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    7/16/26 8:18:00 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Chief Technology Officer Ku Victor sold $280,665 worth of shares (35,649 units at $7.87), decreasing direct ownership by 3% to 1,063,639 units (SEC Form 4) to cover taxes

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    7/8/26 4:32:20 PM ET
    $BFLY
    Medical Electronics
    Health Care

    EVP, CFO Doherty John N. sold $434,818 worth of shares (55,229 units at $7.87), decreasing direct ownership by 4% to 1,454,412 units (SEC Form 4) to satisfy withholding tax

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    7/8/26 4:29:32 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Phanstiel S. Louise bought $571,160 worth of shares (185,261 units at $3.08) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/17/25 4:10:13 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Director Robbins Larry bought $64,471 worth of shares (21,370 units at $3.02) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/15/25 6:20:36 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Director Robbins Larry bought $4,652,773 worth of shares (1,558,541 units at $2.99) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/5/25 5:40:49 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    Financials

    Live finance-specific insights

    View All

    Butterfly Network to Report Second Quarter 2026 Financial Results on July 30, 2026

    Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, announced that it will report second quarter 2026 financial results on Thursday, July 30, 2026, at 8:00 am ET. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and John Doherty, Executive Vice President and Chief Financial Officer, will host a conference call and webcast before the market opens on July 30 to discuss the financial performance and operational progress. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly’s Investor Relations website at Events & Presentations.

    7/16/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Butterfly Network Reports First Quarter 2026 Financial Results

    Delivered Revenue Above Consensus and Beat Adjusted EBITDA Guidance Reaffirmed full year Revenue and Adjusted EBITDA Guidance Delivered quarterly Revenue of $26.5 million in Q1, representing 25% YoY growth Delivered 69% Gross Margin up 600 bps and Adjusted EBITDA of ($6.1M) up 32% YoY Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. Joseph DeVivo, Butterfly's President, Chief Executive Officer and Chairman commented, "Butterfly opened the year with ano

    4/30/26 6:30:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Butterfly Network to Report First Quarter 2026 Financial Results on April 30, 2026

    Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, announced that it will report first quarter 2026 financial results on Thursday, April 30, 2026, at 8:00 am ET. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and John Doherty, Executive Vice President and Chief Financial Officer, will host a conference call and webcast before the market opens on April 30 to discuss the financial performance and operational progress. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly's Investor Relations website at Events & Presentations.

    4/16/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Butterfly Network Inc.

    SC 13D/A - Butterfly Network, Inc. (0001804176) (Subject)

    9/3/24 7:10:06 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Amendment: SEC Form SC 13D/A filed by Butterfly Network Inc.

    SC 13D/A - Butterfly Network, Inc. (0001804176) (Subject)

    8/30/24 4:05:41 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Amendment: SEC Form SC 13G/A filed by Butterfly Network Inc.

    SC 13G/A - Butterfly Network, Inc. (0001804176) (Subject)

    7/8/24 4:32:42 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    Leadership Updates

    Live Leadership Updates

    View All

    A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech

    VMS+™ 4.0 system collects a 2026 Edison Award Gold Medal, advances to NMPA regulatory submission in China, and heads to the AEPC pediatric cardiology meeting in Padua, Italy VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — The AI-cardiac-diagnostics category is one of the more measurable inflection points in the broader medtech sector heading into the second half of 2026. The global AI cardiology market is projected to reach approximately US$2.78 billion in 2026 and climb past US$14 billion by 2034 as software-based diagnostics replace hardware-based imaging across an aging patient base and a healthcare system increasingly cost-pressured at

    5/13/26 9:00:00 AM ET
    $BFLY
    $CTKB
    $HTFL
    Medical Electronics
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Butterfly Network Appoints Caroll H. Neubauer to Board of Directors

    Seasoned Medtech Leader and Former Chairman and CEO of B. Braun of America Brings Deep Healthcare Industry Expertise Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of Caroll H. Neubauer to its Board of Directors, effective May 18, 2026. Mr. Neubauer will serve on the Board's Compensation Committee and Technology Committee. Mr. Neubauer has achieved a distinguished career spanning three decades with B. Braun, including serving for 29 years on the Global Management Board of the B. Braun Group of Companies. During his tenure, he helped grow annual revenue

    5/8/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Butterfly Network Appoints Arun Nagdev, MD as Chief Medical Officer – POCUS

    Prominent POCUS thought leader joins to advance clinical strategy and further Butterfly's mission to democratize ultrasound worldwide. Butterfly Network (NYSE:BFLY), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of Arun Nagdev, MD as Chief Medical Officer – Point-of-Care Ultrasound (POCUS). In this role, Dr. Nagdev will lead the global medical strategy for the Company's core POCUS business, advancing clinical product validation, strengthening customer engagement, and supporting regulatory and clinical development efforts. Dr. Nagdev brings more than 20 years of experience advancing POCUS adoption, educ

    4/21/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care